Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.

Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):367-73. doi: 10.1097/QAI.0b013e3181ae35de.

PMID:
19487951
2.

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group.

Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674.

PMID:
19757993
3.

Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.

Westin MR, Biscione F, Ribeiro KM, Greco DB, Tupinambás U.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):113-7. doi: 10.1089/AID.2013.0084. Epub 2013 Aug 14.

PMID:
23875625
4.

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group.

J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28.

PMID:
21712241
5.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group.

N Engl J Med. 2003 May 29;348(22):2186-95.

6.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group.

N Engl J Med. 2003 May 29;348(22):2175-85. Epub 2003 Mar 13. Erratum in: N Engl J Med. 2003 Sep 11;349(11):1100.

7.

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.

Harris M, Larsen G, Montaner JS.

AIDS. 2008 Jun 19;22(10):1224-6. doi: 10.1097/QAD.0b013e328302f3b5.

PMID:
18525270
8.

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR.

J Clin Virol. 2009 Dec;46(4):305-8. doi: 10.1016/j.jcv.2009.09.025. Epub 2009 Oct 12.

9.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

PMID:
23080489
10.

Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.

Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM; ANRS 138 EASIER Study Group.

J Infect Dis. 2013 Sep;208(6):892-7. doi: 10.1093/infdis/jit280. Epub 2013 Jun 24.

PMID:
23801606
11.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.

AIDS. 2003 Mar 28;17(5):691-8.

PMID:
12646792
12.

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.

PMID:
16280694
13.

A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.

Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillevin L, Lebon P, Launay O.

J Med Virol. 2006 Oct;78(10):1312-7.

PMID:
16927284
14.

Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):135-7.

PMID:
19480091
15.

Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.

Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Moltó J, Martin-Iguacel R, Caum C, Podzamczer D, Clotet B.

HIV Clin Trials. 2009 Nov-Dec;10(6):432-8. doi: 10.1310/hct1006-432.

PMID:
20133273
16.

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.

Wheeler DA, Lalezari JP, Kilby JM, Wheat J, Delehanty J, DeMasi R, Patel I, Salgo M.

J Clin Virol. 2004 Jun;30(2):183-90.

PMID:
15125875
17.

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2008 Sep;62(3):451-5. doi: 10.1093/jac/dkn225. Epub 2008 Jun 13.

PMID:
18552344
19.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group.

Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210.

PMID:
19814627
20.

Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.

Talbot A, Machouf N, Thomas R, Marcotte S, Therrien R, Lessard B, Dufresne S, Lalonde R.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):362-4. doi: 10.1097/QAI.0b013e3181aa1398. No abstract available.

PMID:
19553775

Supplemental Content

Support Center